Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Spartex who wrote (867)	9/8/2003 11:29:21 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 3557

Share of development costs repaid on profitability. Sweeeet.

To: Spartex who wrote (867)	9/8/2003 7:54:04 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

<<Did you buy more calls or stock of regn when it retreated to the 12.5 region?>> It is post-mortal (so it is irrelevant), but FYI I did double my Nov 15 calls (to make up shares lost when margin hit me, plus few extra). VEGF deal came early than expected (than I was expecting, I was bunking on IL-1 Trap PII data (mid Oct). So, if everything (overall market and no Axokine debacle again) is in order we may have one more unexpected pop. This is no recommendation of any kind for any action. Miljenko